InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
60,676.59
(
0.60%
)
Post# of 2342225
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

MasterChi

Send PM Follow Ignore
Followers 36
Posts 3889
Boards Moderated 0
Alias Born 06/23/2017

MasterChi

Re: None

Tuesday, 07/31/2018 12:56:36 PM

Tuesday, July 31, 2018 12:56:36 PM

Post# of 2342225
ABIO short squeeze Single Phase 3 trial may be sufficient for approval of atrial fibrillation indication Phase 3 clinical trial Special Protocol Assessment submission anticipated. 3Q2018Gencaro is in development as potentially the first genetically-targeted treatment for patients with atrial fibrillationGencaro development program previously granted Fast Track Designation by FDA

https://www.otcmarkets.com/stock/ABIO/news/story?e&id=1138815

My post are for entertainment purpose only. I am not a financial advisor. Invest at your own risk.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up